Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O00165

UPID:
HAX1_HUMAN

ALTERNATIVE NAMES:
HS1-associating protein X-1; HS1-binding protein 1

ALTERNATIVE UPACC:
O00165; A8W4W9; A8W4X0; B4DUJ7; Q5VYD5; Q5VYD7; Q96AU4; Q9BS80

BACKGROUND:
HCLS1-associated protein X-1, known for its roles in actin cytoskeleton reorganization and cell survival, interacts with key proteins such as KCNC3 and the Arp2/3 complex. It is implicated in various cellular functions, from slowing KCNC3 channel inactivation to promoting cell migration and potentially regulating intracellular calcium levels. Its ability to inhibit caspases suggests a role in apoptosis regulation.

THERAPEUTIC SIGNIFICANCE:
Given its association with severe congenital neutropenia type 3, a disorder marked by granulopoiesis maturation arrest and susceptibility to infections, HCLS1-associated protein X-1 represents a promising target for therapeutic intervention. Exploring its function further could lead to novel treatments for this and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.